Daytime Mouthpiece Ventilation Combined with Nocturnal Non-Invasive Ventilation in Adults with Duchenne Muscular Dystrophy: A 30-Day Pilot Feasibility Study
Journal of Clinical Medicine · 05.11.2026 · 15 (21) · 8636
DOI: 10.3390/jcm15218636 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 05.11.2026. Verfasst von Anna Annunziata und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Physiopathology, AORN Ospedali dei Colli-Monaldi, 80131 Naples, Italy. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
DMD causes progressive respiratory muscle weakness and chronic alveolar hypoventilation requiring ventilatory support. While nocturnal non-invasive ventilation (NIV) is the standard care, daytime ventilation is often provided with prolonged use of nasal–oronasal masks. These interfaces can cause skin injury, air leaks, and reduced adherence. Mouthpiece ventilation (MPV) provides on-demand pressure support without an interface and may be an alternative for intermittent daytime ventilation.
Objective
To assess the feasibility, safety, and clinical impact of MPV as an adjunct to nocturnal NIV in patients with DMD.
Methods
Six patients with DMD and chronic respiratory failure on nocturnal NIV were enrolled in a 30-day observational pilot study. After training, participants used MPV during daytime. Clinical assessment, arterial blood gases, and quality of life evaluated with the S3-NIV questionnaire were performed at baseline (T0) and after 30 days (T1).
Results
All patients tolerated MPV well, with mean daily use of >16 h. PaCO2 decreased in all patients (from 49.7 ± 7.1 to 43.5 ± 5.7 mmHg; p = 0.031); 4/6 were normocapnic at T1, whereas hypercapnia persisted in two. S3-NIV scores improved from 2.53 ± 0.69 at T0 to 4.87 ± 0.91 at T1 (p = 0.031). Patients reported improved performance of daily activities and better psychological well-being. No MPV-related adverse events occurred.
Conclusions
MPV was feasible, safe, and well tolerated as an adjunct to nocturnal NIV in this small series of patients with DMD over 30 days. Given the small sample and short follow-up, no firm conclusions can be drawn; larger studies with longer follow-up are needed to confirm these findings and define the optimal role of MPV in DMD respiratory management.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Respiratory Physiopathology, AORN Ospedali dei Colli-Monaldi, 80131 Naples, Italy.
- NEMO Clinical Center, AORN Ospedali dei Colli-Monaldi, 80131 Naples, Italy.
- U.O.C. of Pneumology and Respiratory Semi-Intensive Care, Federico II University Hospital, 80131 Naples, Italy.
ORCID-Profile: Antonietta Coppola
Zitieren
APA
Annunziata, A., Mirizzi, A. I., Coppola, A., Valentino, M. R., Saggio, R., Gaglione, P., Gaglione, G., Calafiore, G., Liguori, C., & Fiorentino, G. (2026). Daytime Mouthpiece Ventilation Combined with Nocturnal Non-Invasive Ventilation in Adults with Duchenne Muscular Dystrophy: A 30-Day Pilot Feasibility Study. Journal of Clinical Medicine, 15(21), 8636. https://doi.org/10.3390/jcm15218636
Vancouver
Annunziata A, Mirizzi AI, Coppola A, Valentino MR, Saggio R, Gaglione P, et al. Daytime Mouthpiece Ventilation Combined with Nocturnal Non-Invasive Ventilation in Adults with Duchenne Muscular Dystrophy: A 30-Day Pilot Feasibility Study. Journal of Clinical Medicine. 2026;15(21):8636. doi:10.3390/jcm15218636
BibTeX
@article{Annunziata2026,
author = {Annunziata, Anna and Mirizzi, Angela Irene and Coppola, Antonietta and Valentino, Maria Rosaria and Saggio, Rosa and Gaglione, Pasqualina and Gaglione, Gianfranco and Calafiore, Gennaro and Liguori, Cristina and Fiorentino, Giuseppe},
title = {Daytime Mouthpiece Ventilation Combined with Nocturnal Non-Invasive Ventilation in Adults with Duchenne Muscular Dystrophy: A 30-Day Pilot Feasibility Study},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {21},
pages = {8636},
doi = {10.3390/jcm15218636}
}
EUVIMED